CBD gel shows promise for fragile x behaviors in major trial

NCT ID NCT04977986

Completed Symptom relief Sponsor: Zynerba Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a cannabidiol (CBD) gel, called ZYN002, applied to the skin in 215 children, teens, and young adults with Fragile X syndrome. The goal was to see if it could improve behavioral symptoms like irritability and social withdrawal. Participants received either the CBD gel or a placebo for up to 18 weeks. The trial is complete, and results will show if the gel is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cannabidiol (CBD) gel applied to the skin

What this could lead to

If it works, this could provide a new option to ease behavioral symptoms in people with Fragile X syndrome.

What could go wrong

This is a completed Phase 3 trial, but results are not yet published. CBD may not work better than placebo, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fragile X syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAGILE X SYNDROME

Contacts and locations

Show contact details

Locations

Amnova Clinical Research, LLC

Irvine, California, 92604, United States
Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Central States Research

Tulsa, Oklahoma, 74136, United States
Children's National Medical center

Washington D.C., District of Columbia, 20010, United States
Genetics Clinics Australia

Melbourne, Victoria, 3161, Australia
Greenwood Genetic Center

Greenville, South Carolina, 29605, United States
Health New Zealand - Te Whatu Ora - Wellington Hospital

Newtown, Wellington Region, 6021, New Zealand
Kennedy Krieger Institute

Baltimore, Maryland, 21205, United States
King's College

London, United Kingdom
Lady Cilento Children's Hospital - South Brisbane

Brisbane, Queensland, 4101, Australia
Leicester Clinical Research

Leicester, United Kingdom
Manchester University NHS Foundation Trust

Manchester, United Kingdom
Penn State Hershey Medical Center

Hershey, Pennsylvania, 17033, United States
Phoenix Children's Hospital

Phoenix, Arizona, 85016, United States
Primary Children's Hospital

Salt Lake City, Utah, 84113, United States
Rare Disease Research

Atlanta, Georgia, 30318, United States
Rush University Medical Center

Chicago, Illinois, 60612, United States
Science 37

Culver City, California, 90230, United States
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics

New York, New York, 10029, United States
Thompson Autism Center CHOC

Orange, California, 92868, United States
UC Davis Health System, MIND Institute

Sacramento, California, 95817, United States
University of Edinburgh

Edinburgh, United Kingdom
University of Miami

Miami, Florida, 33136, United States
University of Minnesota Fragile X Clinic (Voyager Clinic)

Minneapolis, Minnesota, 55454, United States
University of Mississippi

Jackson, Mississippi, 39216, United States
Wellcome HRB Clinical Research Facility

Dublin, Ireland
Westmead Children's Hospital

Sydney, New South Wales, 2145, Australia